CClinicalTrials.gg
RecruitingNCT03249012Updated Aug 28, 2024

Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism

An interventional study of Empiric use of Calcium Carbonate and Calcitriol and PTH based Calcium Carbonate and Calcitriol repletion in Hypoparathyroidism Postprocedural and Quality of Life, sponsored by CHU de Quebec-Universite Laval. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-28.

Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare two different protocols commonly used in the management of post thyroidectomy hypoparathyroidism : PTH based calcium repletion and empiric repletion. The investigators aim to compare the quality of life associated with these two protocols in a randomized trial.

Read the detailed description

Enrolled patients will be randomized in two treatment groups. In group 1, all patients will receive calcium carbonate and calcitriol in the post-operative period, with standardized weaning. In group 2, patients will be prescribed calcium carbonate and calcitriol only if their post-operative PTH dosage is 25% or less of the pre-operative dosage, or if post-operative PTH is inferior to 15.

The Short-Form 36 (SF-36) questionnaire (French canadian version) will be used to assess quality of life pre-operatively and at post-op week 1 and 4. Symptoms of hypocalcemia and adverse effects of calcium carbonate and calcitriol will be monitored at week 1 and 4.

02

Conditions studied

  • Hypoparathyroidism Postprocedural
  • Quality of Life

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Total thyroidectomy or completion hemithyroidectomy

Exclusion criteria

Exclusion Criteria:

  • Need for neck dissection
  • Unable to fill in questionnaires (intellectual deficit, severe psychiatric disorder, illiterate, does not speak French or English)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Empiric calcium and calcitriol repletion group

    All patients in this group will receive post-operative calcium carbonate and calcitriol.

    Other: Empiric use of Calcium Carbonate and Calcitriol

  • Experimental
    PTH based repletion group

    Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.

    Other: PTH based Calcium Carbonate and Calcitriol repletion

Interventions

  • OtherEmpiric use of Calcium Carbonate and Calcitriol

    Empiric calcium carbonate and calcitriol repletion

  • OtherPTH based Calcium Carbonate and Calcitriol repletion

    PTH based treatment

05

What researchers measure

Primary outcomes

  1. Change from baseline quality of life at 1 and 4 weeks

    Short Form 36 (SF-36) questionnaire

    Time frame: Pre-op, 1 week post-op and 4 weeks post-op

Secondary outcomes

  1. Occurence and change in pharmacologic adverse effects of calcium carbonate and calcitriol

    A questionnaire about the adverse effects of calcium carbonate and calcitriol will be completed at post-op week 1 and 4

    Time frame: 1 week post-op, 4 weeks post-op

  2. Occurence and change in symptoms of hypocalcemia

    A questionnaire about symptoms of hypocalcemia will be completed at post-op week 1 and 4.

    Time frame: 1 week post-op, 4 weeks post-op

06

Study locations

1 of 1 sites recruiting
07

Registry details

Key details

Study ID
NCT03249012
Lead sponsor
CHU de Quebec-Universite Laval
Responsible party
Jean-Philippe Vézina (Otolaryngologist and Head & Neck Surgeon, CHU de Quebec-Universite Laval) — Principal investigator
First posted
Aug 15, 2017
Start date
Sep 1, 2017
Primary completion
Sep 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Aug 28, 2024

Study contacts

Jean-Philippe Vezina, MD, FRCSC
Contact
jean-philippe.vezina@fmed.ulaval.ca
418-649-0252

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion